Name: NRx Pharmaceuticals, Inc. (NRXP) Financial Statements
Creator: FinSpry

NRx Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

NRx Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.01	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	6.20	13.37	17.03	20.26	10.63
Selling, General & Administrative	13.51	14.22	27.31	74.94	11.44
Operating Expenses	19.70	27.59	44.34	94.43	11.90
Operating Income	-19.70	-27.59	-44.34	-94.43	-11.90
Other Income/Expense
Interest Income	0.04	0.49	0.25	0.00	0.00
Interest Expense	-0.23	-0.12	0.00	0.02	-0.06
Other Income/Expense	-3.78	0.02	4.33	1.39	-0.03
Income
Income Before Tax	-25.13	-30.15	-39.75	-93.06	-51.78
Income Tax Expense	0.00	0.00	-9.30	0.00	0.00
Net Income	-25.13	-30.15	-39.75	-93.06	-51.78
Net Income - Continuous Operations	-25.13	-30.15	-39.75	-93.06	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-19.70	-27.58	-39.75	-93.04	-11.90
EBIT	-19.70	-27.59	-39.75	-93.05	-11.90
Depreciation & Amortization	0.01	0.01	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-2.00	-4.00	-12.00	-74.00	-15.00
Diluted EPS	-2.00	-4.00	-12.00	-74.00	-15.00
Basic Shares Outstanding	10.64	7.58	6.58	4.69	3.43
Diluted Shares Outstanding	10.64	7.58	6.58	4.69	3.43